We serve Chemical Name:2-(carbamoylamino)ethylurea CAS:1852-14-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(carbamoylamino)ethylurea
CAS.NO:1852-14-8
Synonyms:1,1′-Ethylenebisurea;Urea,1,1′-ethylenedi;1,1′-Ethylenediurea;N,N”-Aethandiyl-di-harnstoff;Ethanediurea;Monoethylenediurea;ethylene diurea;N,N”-ethanediyl-di-urea;Dimethylendiharnstoff;N,N”-1,2-Ethanediylbisurea;Aethylendiharnstoff
Molecular Formula:C4H10N4O2
Molecular Weight:146.14800
HS Code:2924199090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:318.7ºC at 760mmHg
Density:1.284g/cm3
Index of Refraction:1.525
PSA:110.24000
Exact Mass:146.08000
LogP:0.50540
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1,1′-Ethylenebisurea chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Aethylendiharnstoff physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Dimethylendiharnstoff Use and application,Urea,1,1′-ethylenedi technical grade,usp/ep/jp grade.
Related News: Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added. 2-(carbamoylamino)ethylurea manufacturer Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added ��The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova. 2-(carbamoylamino)ethylurea supplier This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 2-(carbamoylamino)ethylurea vendor Steven M. Fruchtman, M.D., President and Chief Executive Officer of Onconova, added ��The rigosertib Pre-approval Access Program is a key strategic initiative for Onconova. 2-(carbamoylamino)ethylurea factory It’s the first confirmed Wuhan coronavirus death from outside of mainland China, and brings the total toll to 305.
